These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results
Stoke Therapeutics (STOK) reported mixed Q2 results with losses of 93 cents per share and sales of $9.325 million. Analysts have mixed opinions.
Stoke Therapeutics reported their spring results, which showed the company is still losing money but bringing in some sales. When analysts see mixed results like this, some become more hopeful and others more cautious—so watch how the company's losses and sales change over time to understand if things are getting better or worse.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.